News
Cedar Grove Capital Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...
21h
MarketBeat on MSNHims' Weight Loss Expansion: Real Growth or Just Hype?CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...
Truist analyst Jailendra Singh lowered the firm’s price target on Hims & Hers to $33 from $39 and keeps a Hold rating on the shares as part ...
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...
As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli ...
In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 1566.44 with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results